This innovative approach leverages the specific overexpression of NQO1 in cancer cells to achieve targeted activation of PDT, minimizing damage to surrounding healthy tissues and enhancing the therapeutic efficacy of the treatment [120]. The gene discussed is NQO1; the disease is cancer.